Physician profile
Peter Correnti
NPI 1487659421
$11,180.43
in general payments reported to CMS, 2019-2025
32 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,429 · 2020: $1,077 · 2021: $1,835 · 2022: $2,383 · 2023: $2,339 · 2024: $972 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,457.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,232.82 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $2,088.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,109.59 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $979.72 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $698.29 | 2019-2024 | Camzyos, Eliquis |
| Pfizer INC. | $584.19 | 2019-2024 | |
| Amgen INC. | $386.43 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $340.73 | 2019-2022 | |
| Heartflow, INC. | $292.85 | 2023-2024 | Ffrct |
| Boston Scientific Corporation | $289.94 | 2019-2024 | Watchman Access System, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $269.99 | 2019-2024 | Farxiga |
| Medtronic, INC. | $267.88 | 2021-2023 | Cobalt Dr Mri Surescan, Micra |
| Bayer Healthcare Pharmaceuticals INC. | $209.28 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $205.89 | 2019 | |
| Vifor Pharma, INC. | $200.00 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $162.11 | 2022-2024 | Verquvo |
| Abbott Laboratories | $148.44 | 2019-2023 | Cardiomems |
| Esperion Therapeutics, INC. | $89.44 | 2020-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $78.75 | 2022 | |
| Philips North America LLC | $76.69 | 2020-2023 | |
| Novo Nordisk INC | $76.01 | 2023-2024 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $59.65 | 2023-2025 | Onpattro, Amvuttra |
| Arbor Pharmaceuticals, INC. | $58.25 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $45.45 | 2019-2021 | |
| Janssen Biotech, INC. | $45.42 | 2020-2021 | |
| Akcea Therapeutics, INC. | $36.91 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $35.08 | 2023 | Arcalyst |
| Portola Pharmaceuticals, LLC | $29.62 | 2019 | |
| Kestra Medical Technology Services, INC. | $25.01 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.71 | 2019 | |
| Edwards Lifesciences Corporation | $19.88 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Correnti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.